Back to Search Start Over

Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis

Authors :
Claudia M. van Tiel
Roy Schrijver
Dorothee Atzler
Aldo Jongejan
Oliver Soehnlein
Marnix Lameijer
Menno P.J. de Winther
Francois Fay
Suzanne A. B. M. Aarts
Barbara Zarzycka
Bram Slütter
Christian Weber
Jun Tang
Perry D. Moerland
Norbert Gerdes
Boris Bleijlevens
Myrthe den Toom
Raphaël Duivenvoorden
Esther Lutgens
Tom Seijkens
Linda Beckers
Pascal J. H. Kusters
Remco T. A. Megens
Marion J.J. Gijbels
Gijs Kooij
Cornelis van 't Veer
Johan Kuiper
Gerry A. F. Nicolaes
Gert Vriend
Louis Boon
Edward A. Fisher
Willem J. M. Mulder
Samantha Baxter
Johan Duchene
Maria Aslani
Marten A. Hoeksema
Biomedische Technologie
Promovendi CD
Biochemie
Moleculaire Genetica
Pathologie
RS: CARIM - R3.06 - The vulnerable plaque: makers and markers
RS: CARIM - R2.06 - Intermediate cardiac metabolism
RS: CARIM - R3.07 - Structure-function analysis of the chemokine interactome for therapeutic targeting and imaging in atherosclerosis
RS: CARIM - R1.01 - Blood proteins & engineering
Medical Biochemistry
ACS - Amsterdam Cardiovascular Sciences
Graduate School
Other departments
Center of Experimental and Molecular Medicine
APH - Methodology
Epidemiology and Data Science
APH - Personalized Medicine
AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
Other Research
Nephrology
ACS - Atherosclerosis & ischemic syndromes
ACS - Pulmonary hypertension & thrombosis
Molecular cell biology and Immunology
Amsterdam Neuroscience - Neuroinfection & -inflammation
Source :
Journal of the American College of Cardiology, 71(5), 527-542. Elsevier Science, Journal of the American College of Cardiology, Journal of the American College of Cardiology, 71(5), 527-542, Journal of the American College of Cardiology, 71, 5, pp. 527-542, Journal of the American College of Cardiology, 71(5), 527-542. Elsevier USA, Seijkens, T T P, van Tiel, C M, Kusters, P J H, Atzler, D, Soehnlein, O, Zarzycka, B, Aarts, S A B M, Lameijer, M, Gijbels, M J, Beckers, L, den Toom, M, Slütter, B, Kuiper, J, Duchene, J, Aslani, M, Megens, R T A, van ‘t Veer, C, Kooij, G, Schrijver, R, Hoeksema, M A, Boon, L, Fay, F, Tang, J, Baxter, S, Jongejan, A, Moerland, P D, Vriend, G, Bleijlevens, B, Fisher, E A, Duivenvoorden, R, Gerdes, N, de Winther, M P J, Nicolaes, G A, Mulder, W J M, Weber, C & Lutgens, E 2018, ' Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis ', Journal of the American College of Cardiology, vol. 71, no. 5, pp. 527-542 . https://doi.org/10.1016/j.jacc.2017.11.055, https://doi.org/10.1016/j.jacc.2017.11.055, Journal of the American College of Cardiology, 71, 527-542
Publication Year :
2018

Abstract

Background Disrupting the costimulatory CD40-CD40L dyad reduces atherosclerosis, but can result in immune suppression. The authors recently identified small molecule inhibitors that block the interaction between CD40 and tumor necrosis factor receptor-associated factor (TRAF) 6 (TRAF-STOPs), while leaving CD40-TRAF2/3/5 interactions intact, thereby preserving CD40-mediated immunity. Objectives This study evaluates the potential of TRAF-STOP treatment in atherosclerosis. Methods The effects of TRAF-STOPs on atherosclerosis were investigated in apolipoprotein E deficient (Apoe−/−) mice. Recombinant high-density lipoprotein (rHDL) nanoparticles were used to target TRAF-STOPs to macrophages. Results TRAF-STOP treatment of young Apoe−/− mice reduced atherosclerosis by reducing CD40 and integrin expression in classical monocytes, thereby hampering monocyte recruitment. When Apoe−/− mice with established atherosclerosis were treated with TRAF-STOPs, plaque progression was halted, and plaques contained an increase in collagen, developed small necrotic cores, and contained only a few immune cells. TRAF-STOP treatment did not impair “classical” immune pathways of CD40, including T-cell proliferation and costimulation, Ig isotype switching, or germinal center formation, but reduced CD40 and β2-integrin expression in inflammatory monocytes. In vitro testing and transcriptional profiling showed that TRAF-STOPs are effective in reducing macrophage migration and activation, which could be attributed to reduced phosphorylation of signaling intermediates of the canonical NF-κB pathway. To target TRAF-STOPs specifically to macrophages, TRAF-STOP 6877002 was incorporated into rHDL nanoparticles. Six weeks of rHDL-6877002 treatment attenuated the initiation of atherosclerosis in Apoe−/− mice. Conclusions TRAF-STOPs can overcome the current limitations of long-term CD40 inhibition in atherosclerosis and have the potential to become a future therapeutic for atherosclerosis.<br />Central Illustration

Details

Language :
English
ISSN :
07351097
Database :
OpenAIRE
Journal :
Journal of the American College of Cardiology, 71(5), 527-542. Elsevier Science, Journal of the American College of Cardiology, Journal of the American College of Cardiology, 71(5), 527-542, Journal of the American College of Cardiology, 71, 5, pp. 527-542, Journal of the American College of Cardiology, 71(5), 527-542. Elsevier USA, Seijkens, T T P, van Tiel, C M, Kusters, P J H, Atzler, D, Soehnlein, O, Zarzycka, B, Aarts, S A B M, Lameijer, M, Gijbels, M J, Beckers, L, den Toom, M, Slütter, B, Kuiper, J, Duchene, J, Aslani, M, Megens, R T A, van ‘t Veer, C, Kooij, G, Schrijver, R, Hoeksema, M A, Boon, L, Fay, F, Tang, J, Baxter, S, Jongejan, A, Moerland, P D, Vriend, G, Bleijlevens, B, Fisher, E A, Duivenvoorden, R, Gerdes, N, de Winther, M P J, Nicolaes, G A, Mulder, W J M, Weber, C & Lutgens, E 2018, ' Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis ', Journal of the American College of Cardiology, vol. 71, no. 5, pp. 527-542 . https://doi.org/10.1016/j.jacc.2017.11.055, https://doi.org/10.1016/j.jacc.2017.11.055, Journal of the American College of Cardiology, 71, 527-542
Accession number :
edsair.doi.dedup.....cca6a3b34a4eaed1e2703cd007d5bc8d
Full Text :
https://doi.org/10.1016/j.jacc.2017.11.055